Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glauco-Health and Glauco-Select in Glaucoma and Diabetic Retinopathy
NCT02984813Phase 1Terminated
- Sponsor
- New York Eye and Ear Infirmary of Mount Sinai
- Start
- Apr 2016
- Primary completion
- Jan 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in open-angle glaucoma (OAG) and diabetic retinopathy (DR) (3 arms), sponsored by New York Eye and Ear Infirmary of Mount Sinai. Primary endpoint: Flavoprotein fluorescence index at 3 months. Started Apr 2016; status: terminated.
02
Conditions
open-angle glaucoma (OAG)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT02984813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02984813.